FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Status:
Completed
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401
as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and
as single agent in patients with other solid malignancies based on RECIST 1.1.